End of the bare metal stent era?
Second-generation drug eluting stents (2g-DES) have lower rates of stent thrombosis (ST) than bare metal stents (BMS). Second-generation DES have exceedingly low rates of very late ST, significantly improving on first-generation drug eluting stents (1g-DES) and similar to BMS. Emerging drug-coated stent (DCS) technology appears superior to BMS in patients unable to tolerate prolonged dual antiplatelet therapy (DAPT).